交易中 07-01 11:05:42 美东时间
+0.030
+1.73%
Morgan Stanley analyst Judah Frommer downgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Underweight.
06-18 18:48
今日重点评级关注:摩根大通:上调Camp4 Therapeutics评级至"超配",目标价从5美元升至9美元;Canaccord Genuity:维持Rhythm制药"买入"评级,目标价从143美元升至151美元
06-17 11:32
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. UBS slashed the price target for Sunrun Inc. (NASDAQ:RUN) from $23 to $20. UBS analyst Jon Windham maintained ...
06-16 20:26
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) with a Buy and lowers the price target from $6 to $4.
06-16 18:19
enGene Holdings press release (ENGN): Q2 GAAP EPS of $0.43. As of April 30, 2026, cash, cash equivalents and marketable securities were $285.2 million providing significant operational flexibility. To...
06-15 22:12
enGene Holdings ( ($ENGN) ) has provided an announcement. On June 15, 2026, enG...
06-15 21:54
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.47) by 8.51 percent. This is a 15.69 percent increase over losses of $(0.51) per share from the same period last year.
06-15 21:06
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从15美元升至35美元;韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从36美元升至37美元
05-11 15:43
enGene stock sinks after Phase 2 bladder cancer trial shows durability concerns. Analysts slash price forecasts as the sell-off intensifies.
05-08 23:34
(来源:药时代) 2026年5月7日,加拿大药企enGene Holdings(NASDAQ: ENGN)遭遇资本巨震,股价暴跌约80%,报1.72美元/股...
05-08 18:41